<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578902</url>
  </required_header>
  <id_info>
    <org_study_id>371-2006</org_study_id>
    <nct_id>NCT01578902</nct_id>
  </id_info>
  <brief_title>Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer</brief_title>
  <acronym>pHART3</acronym>
  <official_title>Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer (pHART 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Association of Radiation Oncology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of a short course of&#xD;
      radiotherapy (35 Gy / 5 fractions / 29 days) for the treatment of low-risk prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale for Proposed Study With the availability of intensity modulated radiotherapy (IMRT)&#xD;
      at the Odette Cancer Centre (OCC), there is an opportunity to explore the use of a much more&#xD;
      intensive hypofractionation schedule for prostate cancer. Using an alpha/beta ratio of 1.3, a&#xD;
      dose of 35 Gy in 5 fractions would be equivalent to 88 Gy delivered in 2 Gy fractions. For&#xD;
      normal tissues (alpha/beta value of 2), this would be equivalent to 78 Gy in 2 Gy fractions.&#xD;
      As such, the linear quadratic equation predicts that 35 Gy in 5 fractions should not result&#xD;
      in any increased late toxicity for normal tissues compared to standard dose escalated&#xD;
      radiotherapy. However, the biological dose to the prostate cancer would be significantly&#xD;
      increased. As a safety precaution for this study proposal, the investigators propose to&#xD;
      deliver 35 Gy in 5 fractions over 5 weeks (one radiotherapy fraction of 7 Gy per week) to&#xD;
      allow for normal tissue repair.&#xD;
&#xD;
      With IMRT, it is expected that there will be superior conformality of the high dose region&#xD;
      around the target volume. As well, the use of daily on-line imaging will allow us to&#xD;
      eliminate interfraction prostate motion errors and use tighter planning target volume margins&#xD;
      for any residual intrafraction motion. At OCC, such an approach has already been shown to be&#xD;
      feasible and is currently employed in the phase 1/2 concomitant boost study for high risk&#xD;
      prostate cancer.&#xD;
&#xD;
      If proven to be safe and effective, such a hypofractionated radiotherapy schedule may have&#xD;
      significant practical advantages as well. With only 1 fraction of radiotherapy delivered each&#xD;
      week (for a total of 5 weeks), there are huge savings in resource utilization and increased&#xD;
      convenience for patients.&#xD;
&#xD;
      The investigators propose to start a small phase 1 study to explore the use of this dose&#xD;
      fractionation for men with low risk prostate cancer. The primary endpoint for this small&#xD;
      pilot study would be acute and late normal tissue toxicities. If proven to be feasible and&#xD;
      safe, external peer-reviewed funding will be sought to further explore this novel treatment&#xD;
      schedule in a larger phase 2 setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 3+ Gastrointestinal Toxicity</measure>
    <time_frame>Acute period (up to 6 months)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3+ Genitourinary Toxicity</measure>
    <time_frame>Acute (up to 6 months) and Late (6 months and after)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3+ Rectal and Urinary Toxicity</measure>
    <time_frame>Late (6 months and after)</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Quality of Life</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical (ie. Prostate Specific Antigen) Disease Free Survival</measure>
    <time_frame>5 year</time_frame>
    <description>Failure = Follow-up PSA greater than nadir PSA + 2 ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Positive Rate</measure>
    <time_frame>3 year</time_frame>
    <description>Patients were biopsied at 3 years post treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Hypofractionated radiotherapy using SABR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic radiation: 35Gy in 5 fractions over 29 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic ablative body radiotherapy</intervention_name>
    <description>35Gy/5 fractions/29 days</description>
    <arm_group_label>Hypofractionated radiotherapy using SABR</arm_group_label>
    <other_name>standard linear accelerator delivery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed (Appendix A)&#xD;
&#xD;
          -  Adult men greater than 18 years of age&#xD;
&#xD;
          -  Histologically confirmed diagnosis of adenocarcinoma of the prostate (centrally&#xD;
             reviewed).&#xD;
&#xD;
          -  Clinical stage T1-T2b, Gleason Score &lt; 6, and PSA &lt; 10 ng/mL&#xD;
&#xD;
          -  Less than 50% of biopsy cores +ve for cancer&#xD;
&#xD;
          -  Less than 50% overall surface area involved with cancer&#xD;
&#xD;
          -  Neoadjuvant hormone suppression therapy is allowed. However, PSA, must have been&#xD;
             performed within 2 months of starting androgen suppression therapy. If androgen&#xD;
             suppression therapy has been started LHRH agonist must be continued for a minimum of 3&#xD;
             months before initiation of gold fiducial marker insertion &amp; radiotherapy planning.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior pelvic radiotherapy.&#xD;
&#xD;
          -  Concurrent anticoagulation medication (if it is unsafe to discontinue for gold seed&#xD;
             insertion)&#xD;
&#xD;
          -  Diagnosis of bleeding diathesis&#xD;
&#xD;
          -  Presence of a hip prosthesis&#xD;
&#xD;
          -  Pelvic girth &gt;40cm (to ensure visibility of gold seeds on electronic portal imaging&#xD;
             device)&#xD;
&#xD;
          -  Large prostate (&gt; 60 cm3) on imaging&#xD;
&#xD;
          -  Severe lower urinary tract symptoms (International Prostate Symptom Score &gt; 15 or&#xD;
             nocturia &gt; 3)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Loblaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Cheung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <results_first_submitted>October 12, 2017</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Hypofractionation</keyword>
  <keyword>Low Risk Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were prospectively recruited from the Odette Cancer Centre from Oct 2006 to July 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hypofractionated Radiation</title>
          <description>35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.&#xD;
Hypofractionated radiotherapy: 35Gy/5 fractions/29 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>Inclusion criteria were men over 18 years of age with histologically confirmed diagnosis of adenocarcinoma of the prostate. Only patients with clinical stage T1-T2b (TNM 2002) [18] Gleason Sum 66 and PSA 610 ng/ml were eligible. Neoadjuvant androgen deprivation therapy (ADT) was allowed for cytoreduction. Patients were excluded if they had prior pelvic radiation therapy, a bleeding diathesis which precluded safe gold seed insertion, the presence of hip prosthesis or pelvic girth &gt;40 cm. Lastly, prostate size &gt;90cm3 on imaging or severe lower urinary tract symptoms (IPSS &gt; 19)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="42" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Grade 3+ Gastrointestinal Toxicity</title>
        <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
        <time_frame>Acute period (up to 6 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Radiation</title>
            <description>35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.&#xD;
The co-primary outcome variable (Grade 3+ acute gastrointestinal toxicity) was observed in 0% of patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3+ Gastrointestinal Toxicity</title>
          <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 3+ Genitourinary Toxicity</title>
        <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
        <time_frame>Acute (up to 6 months) and Late (6 months and after)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Radiation</title>
            <description>35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.&#xD;
The co-primary endpoint (Grade 3+ acute genitourinary toxicity) was observed in 1% (1/84) patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3+ Genitourinary Toxicity</title>
          <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 3+ Rectal and Urinary Toxicity</title>
        <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
        <time_frame>Late (6 months and after)</time_frame>
        <population>low risk prostate cancer patients were treated with SABR 35Gy in 5 fractions over 29 days</population>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Radiation</title>
            <description>35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.&#xD;
Hypofractionated radiotherapy: 35Gy/5 fractions/29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3+ Rectal and Urinary Toxicity</title>
          <description>Common Terminology Criteria for Adverse Events (CTCAE) v3.0</description>
          <population>low risk prostate cancer patients were treated with SABR 35Gy in 5 fractions over 29 days</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute GU grade 3+ toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute GI grade 3+ toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late GU grade 3+ toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late GI grade 3+ toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Quality of Life</title>
        <description>Expanded Prostate Cancer Index Composite (EPIC)</description>
        <time_frame>up to 5 years</time_frame>
        <population>Patients were low risk prostate cancer patients treated with SABR 35Gy in 5 fractions over 29 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Radiotherapy Using SABR</title>
            <description>Stereotactic radiation: 35Gy in 5 fractions over 29 days&#xD;
Stereotactic ablative body radiotherapy: 35Gy/5 fractions/29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Quality of Life</title>
          <description>Expanded Prostate Cancer Index Composite (EPIC)</description>
          <population>Patients were low risk prostate cancer patients treated with SABR 35Gy in 5 fractions over 29 days.</population>
          <units>percentage with change in QOL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bowel quality of life change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder quality of life change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual quality of life change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical (ie. Prostate Specific Antigen) Disease Free Survival</title>
        <description>Failure = Follow-up PSA greater than nadir PSA + 2 ng/ml</description>
        <time_frame>5 year</time_frame>
        <population>low risk prostate cancer patients treated with SABR 35 Gy in 5 fractions over 29 days</population>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Radiation</title>
            <description>35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.&#xD;
Hypofractionated radiotherapy: 35Gy/5 fractions/29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical (ie. Prostate Specific Antigen) Disease Free Survival</title>
          <description>Failure = Follow-up PSA greater than nadir PSA + 2 ng/ml</description>
          <population>low risk prostate cancer patients treated with SABR 35 Gy in 5 fractions over 29 days</population>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy Positive Rate</title>
        <description>Patients were biopsied at 3 years post treatment</description>
        <time_frame>3 year</time_frame>
        <population>low risk prostate cancer patients treated with SABR 35 Gy in 5 fractions over 29 days</population>
        <group_list>
          <group group_id="O1">
            <title>Hypofractionated Radiation</title>
            <description>35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.&#xD;
Hypofractionated radiotherapy: 35Gy/5 fractions/29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy Positive Rate</title>
          <description>Patients were biopsied at 3 years post treatment</description>
          <population>low risk prostate cancer patients treated with SABR 35 Gy in 5 fractions over 29 days</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hypofractionated Radiation</title>
          <description>35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.&#xD;
The co-primary outcome variable (Grade 3+ acute gastrointestinal toxicity) was observed in 0% of patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>rectalcutaneous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute grade 2 gastrointestinal toxicity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>late grade 2 gastrointestinal toxicity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>late grade 3+ GI toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute grade 2 genitourinary</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>late grade 2 genitourinary toxicity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>late grade 3+ GU toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>acute grade 3+ GU toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Andrew Loblaw, Director GU Radiation Trials</name_or_title>
      <organization>Sunnybrook Research Institute</organization>
      <phone>4164804806</phone>
      <email>andrew.loblaw@sunnybrook.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

